Upcoming Conference Schedules, Orphan Drug Designations and Stock Price Updates - Research Report on Pfizer, ICU Medical, CONMED, Gentium, and Repros Therapeutics Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 25, 2013 NEW YORK, November 25, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), ICU Medical, Inc. (NASDAQ: ICUI), CONMED Corporation (NASDAQ: CNMD), Gentium S.p.A (NASDAQ: GENT), and Repros Therapeutics Inc. (NASDAQ: RPRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Pfizer Inc. Research Report On November 20, 2013, Pfizer Inc.'s (Pfizer) stock went up by 0.82% to $31.92 per share. However, over the previous three trading sessions, Pfizer's stock went down 0.87%, compared to the S&P500 which went down by 0.93% during the same trading period. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d702_PFE -- ICU Medical, Inc. Research Report On November 20, 2013, ICU Medical, Inc.'s (ICU Medical) stock closed at $63.21 per share, reflecting an increase of 3.32% over the previous day closing. Over the past three trading day period, ICU Medical's stock went up by 1.17%, compared to the Dow Jones Industrial Average which went down by 0.38% during the same period. The Full Research Report on ICU Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/be3b_ICUI -- CONMED Corporation Research Report On November 15, 2013, CONMED Corporation (CONMED) announced that the Company will participate in the Piper Jaffray 25th Annual Healthcare Conference on December 4, 2013, in New York City at 11:30 a.m. EST. According to CONMED, its President and CEO, Mr. Joseph J. Corasanti will discuss the Company's business, and the live webcast of the presentation will be made available on its corporate website under the investors section. Also, the replay of the same will be available through December 13, 2013 at the same location. The Full Research Report on CONMED Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/a9b1_CNMD -- Gentium S.p.A Research Report On November 19, 2013, Gentium S.p.A (Gentium) announced that the European Commission (EC) has granted Orphan Drug Designation to Defibrotide, the Company's lead product candidate, for the prevention of Graft versus Host Disease (GvHD). The Company stated that the designation follows a positive opinion released by the Committee for Orphan Medicinal Products of the European Medicines Agency, on October 10, 2013. Dr. Khalid Islam, Gentium Chairman and CEO stated, "We are pleased to receive Orphan Drug Designation for this second indication by the EMA for Defibrotide for the prevention of GvHD. The granting of this Orphan Drug Designation is another important milestone for Defibrotide as we continue our development of the product to address significant unmet medical need for this potentially life-threatening disease. We look forward to planning and initiating additional studies to explore the full potential of Defibrotide in this indication." The Full Research Report on Gentium S.p.A - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/e100_GENT -- Repros Therapeutics Inc. Research Report On November 20, 2013, Repros Therapeutics Inc.'s (Repros Therapeutics) stock was down 1.78%, closing the day at $14.33 per share. The Company's stock declined 5.16% over the past three trading days, compared to the Nasdaq composite which went down 1.62% during the same trading period. The Full Research Report on Repros Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/2334_RPRX ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 1.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 2.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 3.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 4.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 5.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Upcoming Conference Schedules, Orphan Drug Designations and Stock Price Updates - Research Report on Pfizer, ICU Medical,
Press spacebar to pause and continue. Press esc to stop.